Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
CIPLA LIMITED |
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 1184.70 INR | -0.12% | +1.74% | +10.04% | |
| 04:20am | INDIA STOCKS-Indian shares set to open lower tracking Asian peers | RE |
| Oct. 02 | Cipla Completes Sale of 51% Stake in UAE-based Saba Investment | MT |
| Sales 2024 * | 254 B 3,057 M | Sales 2025 * | 280 B 3,370 M | Capitalization | 958 B 11 509 M |
|---|---|---|---|---|---|
| Net income 2024 * | 36,749 M 442 M | Net income 2025 * | 42,558 M 512 M | EV / Sales 2024 * | 3,57x |
| Net cash position 2024 * | 48,545 M 583 M | Net cash position 2025 * | 73,819 M 887 M | EV / Sales 2025 * | 3,15x |
| P/E ratio 2024 * | 26,1x | P/E ratio 2025 * | 22,6x | Employees | - |
| Yield 2024 * | 0,60% | Yield 2025 * | 0,67% | Free-Float | 64.30% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -0.26% | ||
| 1 week | +1.67% | ||
| Current month | -0.26% | ||
| 1 month | -4.50% | ||
| 3 months | +18.09% | ||
| 6 months | +32.71% | ||
| Current year | +9.95% |
1 week
1 158.90
1 199.20
1 month
1 158.901 267.00
Current year
852.001 277.90
1 year
852.001 277.90
3 years
706.501 277.90
5 years
355.301 277.90
10 years
355.301 277.90
| Managers | Title | Age | Since |
|---|---|---|---|
Umang Vohra
CEO | Chief Executive Officer | 51 | 2016 |
| Director/Board Member | 82 | 2011 | |
Dinesh Jain
PRN | Corporate Officer/Principal | - | 2022 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 87 | 1972 | |
| Director/Board Member | 82 | 2011 | |
| Director/Board Member | 48 | 2015 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-10-03 | 1184.70 | -0.12% | 1 057 046 |
| 23-09-29 | 1186.15 | +1.90% | 1,878,381 |
| 23-09-28 | 1164.05 | -1.39% | 1,303,811 |
| 23-09-27 | 1180.50 | +1.45% | 2,165,043 |
| 23-09-26 | 1163.65 | -1.33% | 1,056,359 |
Delayed Quote NSE India Stock Exchange, October 03, 2023 at 02:21 am EDT
More quotes
Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products.
Net sales by source of income break down between sale of products (96.9%) and services (3.1%).
Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).
Sector
Pharmaceuticals
Calendar
2023-11-07
- Q2 2024 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
36
Last Close Price
1186.15INR
Average target price
1178.72INR
Spread / Average Target
-0.63%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| +9.95% | 11 511 M $ | |
| -28.83% | 956 M $ | |
| -23.14% | 479 M $ | |
| +8.33% | 120 M $ | |
| +83.76% | 63 M $ | |
| +37.83% | 665 M $ | |
| +3.15% | 525 M $ | |
| -10.26% | 74 M $ | |
| -12.43% | 99 M $ | |
| +40.77% | 1 397 M $ |
